Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Mazen Animal Health Inc. currently manages 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 3 distinct examiners, ensuring that each application receives an independent review. This distribution across 3 distinct art units further indicates that the company's innovations cover a variety of technical classifications within the life sciences field.
BLUMEL, BENJAMIN P is the busiest examiner for the portfolio, currently responsible for 1 pending office action. Because each of the 3 pending office actions is assigned to a different examiner, no single individual has a dominant influence over the company's current prosecution outcomes. This spread across 3 distinct examiners allows the company to engage with multiple perspectives at the USPTO.
The presence of 3 distinct art units suggests a diversified technical focus for the company's active filings. BLUMEL, BENJAMIN P handles 1 pending office action, which is consistent with the workload of the other examiners involved. This balanced approach across 3 pending office actions requires the company to manage different examiner styles and technical requirements simultaneously.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BLUMEL, BENJAMIN P | 1 | 70.7% | +30.6% |
| CHATTERJEE, JAYANTA | 1 | 44.0% | +70.1% |
| BUCKMASTER, MARLENE VRENI | 1 | 28.1% | +74.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17805396 | ORAL ADMINISTRATION OF CORONAVIRUS SPIKE PROTEIN FOR ALTERING CYTOKINE LEVELS AND PROVIDING PASSIVE IMMUNITY TO NEWBORN PIGS | BUCKMASTER, MARLENE VRENI | 147d overdue |
| 18756402 | EXPRESSION OF EIMERIA SEQUENCES IN PLANTS AND PLANT PRODUCED VACCINE FOR SAME | CHATTERJEE, JAYANTA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17805396 | ORAL ADMINISTRATION OF CORONAVIRUS SPIKE PROTEIN FOR ALTERING CYTOKINE LEVELS AND PROVIDING PASSIVE IMMUNITY TO NEWBORN PIGS | BUCKMASTER, MARLENE VRENI | 147d overdue |
| 18989993 | METHODS FOR PROVIDING PROTECTION TO PORCINE EPIDEMIC DIARRHEA VIRUS (PEDV) WITH A PLANT PRODUCED VACCINE | BLUMEL, BENJAMIN P | — |
| 18756402 | EXPRESSION OF EIMERIA SEQUENCES IN PLANTS AND PLANT PRODUCED VACCINE FOR SAME | CHATTERJEE, JAYANTA | — |
| Art Unit | Apps |
|---|---|
| 1671 | 1 |
| 1662 | 1 |
| 1672 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18989993 | METHODS FOR PROVIDING PROTECTION TO PORCINE EPIDEMIC DIARRHEA VIRUS (PEDV) WITH A PLANT PRODUCED VACCINE | BLUMEL, BENJAMIN P | 1671 | §102§112DP | Non-Final OA | — | Pending | Dec 20, 2024 |
| 18756402 | EXPRESSION OF EIMERIA SEQUENCES IN PLANTS AND PLANT PRODUCED VACCINE FOR SAME | CHATTERJEE, JAYANTA | 1662 | §102§103§112 | Non-Final OA | — | Pending | Jun 27, 2024 |
| 17805396 | ORAL ADMINISTRATION OF CORONAVIRUS SPIKE PROTEIN FOR ALTERING CYTOKINE LEVELS AND PROVIDING PASSIVE IMMUNITY TO NEWBORN PIGS | BUCKMASTER, MARLENE VRENI | 1672 | §103§112Other | Final Rejection | 147d overdue | Pending | Jun 03, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMazen Animal Health Inc. has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Benjamin P Blumel has the most, with 1 of Mazen Animal Health Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
